Rituximab

Generic Name: Rituximab

Brand Names: MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 174722-31-7

Unique Ingredient Identifier: 4F4X42SYQ6

Background: Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication: Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions: Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)

Associated Therapies: -

Clinical Trials

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

Phase 2

Recruiting

Conditions: Waldenström's Macroglobulinemia

Interventions: Drug: Zanubrutinib
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2023-08-07

Last Posted Date: 2023-09-14

Lead Sponsor: Shanghai Changzheng Hospital

Target Recruit Count: 60

Registration Number: NCT05979948

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Rituxmab Versus IL-6 in Treating ILD

Phase 2

Completed

Conditions: Scleroderma
Interstitial Lung Disease

Interventions: Drug: IL6 inhibitor
Drug: Rituximab

First Posted Date: 2023-07-27

Last Posted Date: 2023-11-15

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT05963048

Locations: 🇪🇬
Manal Hassanien, Assiut, Yes, Egypt

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Mantle Cell Lymphoma (MCL)

Interventions: Drug: Acalabrutinib
Drug: Venetoclax
Drug: Rituximab

First Posted Date: 2023-07-19

Last Posted Date: 2024-11-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 108

Registration Number: NCT05951959

Locations: 🇬🇧
Research Site, Plymouth, United Kingdom

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Phase 2

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Acalabrutinib
Biological: Rituximab

First Posted Date: 2023-07-19

Last Posted Date: 2024-12-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT05952024

Locations: 🇵🇷
Research Site, San Juan, Puerto Rico

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Phase 1

Recruiting

Conditions: Relapsed/Refractory B-Cell Lymphoma

Interventions: Drug: FT522
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2023-07-18

Last Posted Date: 2024-07-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 166

Registration Number: NCT05950334

Locations: 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Phase 3

Recruiting

Conditions: CLL
Small-Cell Lymphoma
Lymphoma, Small Lymphocytic
SLL
Leukemia, Chronic Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Nemtabrutinib
Drug: Venetoclax
Biological: Rituximab

First Posted Date: 2023-07-17

Last Posted Date: 2024-12-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 720

Registration Number: NCT05947851

Locations: 🇹🇷
Mega Medipol-Hematology ( Site 4904), İstanbul, Turkey
🇺🇸
Highlands Oncology Group ( Site 5405), Springdale, Arkansas, United States
🇺🇸
MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach, California, United States

and more 46 locations